Abstract The b 1 -adrenergic antagonist metoprolol improves cardiac function in animals and patients with chronic heart failure, isolated mitral regurgitation (MR), and ischemic heart disease, though the molecular mechanisms remain incompletely understood. Metoprolol has been reported to upregulate cardiac expression of b 3 -adrenergic receptors (b 3 AR) in animal models. Myocardial b 3 AR signaling via neuronal nitric oxide synthase (nNOS) activation has recently emerged as a cardioprotective pathway. We tested whether chronic b 1 -adrenergic blockade with metoprolol enhances myocardial b 3 AR coupling with nitric oxidestimulated cyclic guanosine monophosphate (b 3 AR/NOcGMP) signaling in the MR-induced, volume-overloaded heart. We compared the expression, distribution, and inducible activation of b 3 AR/NO-cGMP signaling proteins within myocardial membrane microdomains in dogs (canines) with surgically induced MR, those also treated with metoprolol succinate (MR?bB), and unoperated controls. b 3 AR mRNA transcripts, normalized to housekeeping gene RPLP1, increased 4.4 9 10 3 -and 3.2 9 10 2
Abstract The b 1 -adrenergic antagonist metoprolol improves cardiac function in animals and patients with chronic heart failure, isolated mitral regurgitation (MR), and ischemic heart disease, though the molecular mechanisms remain incompletely understood. Metoprolol has been reported to upregulate cardiac expression of b 3 -adrenergic receptors (b 3 AR) in animal models. Myocardial b 3 AR signaling via neuronal nitric oxide synthase (nNOS) activation has recently emerged as a cardioprotective pathway. We tested whether chronic b 1 -adrenergic blockade with metoprolol enhances myocardial b 3 AR coupling with nitric oxidestimulated cyclic guanosine monophosphate (b 3 AR/NOcGMP) signaling in the MR-induced, volume-overloaded heart. We compared the expression, distribution, and inducible activation of b 3 AR/NO-cGMP signaling proteins within myocardial membrane microdomains in dogs (canines) with surgically induced MR, those also treated with metoprolol succinate (MR?bB), and unoperated controls. [4, 6, 16, 19, 27, 31, 38, 53] , though many remain incompletely understood. In addition to disrupting the chronic adrenergic toxicity underlying heart failure (HF), bBs improve b-adrenoceptor (bAR) function largely by reversing the downregulation of myocardial b 1 -and b 2 AR [18, 59] and by countering the upregulation of G protein-coupled receptor kinase 2 (GRK2) expression [21] otherwise induced by chronic sympathetic activation. Thus, chronic bB therapy recouples bAR and G protein activity and restores bAR responsiveness. While studies of the effect of bB on bAR signaling in the diseased heart focus predominantly on b 1 -and b 2 ARs, few have examined its effect on b 3 AR. Myocardial b 2 AR expression is reportedly increased in HF animal models and patients [8, 35] and, in limited studies, even more so with chronic bB therapy [51, 64] . Recently, b 3 AR activation has been shown to induce nitric oxide (NO)-mediated cardioprotection in animal models of cardiac pressure overload, neurohormoneinduced hypertrophy, myocardial ischemia/reperfusion injury, and acute myocardial infarction [1, 5, 14, 41, 60] . Chronic b 1 -blockade (b 1 B) might well amplify cardioprotective b 3 AR signaling in the pathologically remodeled heart. Intriguing but little explored, such a mechanism would suggest novel approaches to enhancing innate cardioprotective signaling while assuring compatibility with current guideline-directed medical therapy.
bAR signaling regulates cardiac myocyte contractility and hypertrophic signaling and, under normal physiological conditions, is modulated by NO via both direct [i.e., soluble guanylyl cyclase (sGC) activation] and indirect actions (e.g. S-nitrosylation, tyrosine nitration). NO activation of sGC, with its subsequent production of cyclic guanosine monophosphate (cGMP), blunts b 1 -and b 2 AR-stimulated cardiac contractility [55] . S-nitrosylation of GRK2 (also known as b-adrenergic receptor kinase 1 or bARK1) inhibits the desensitization and downregulation of b 1 -and b 2 ARs [61] .
Conversely, b 2 -and b 3 AR signaling can activate NO synthase (NOS), thereby coupling bAR signaling with NO signaling. Unlike b 1 -and b 2 ARs, b 3 ARs are stimulated at high catecholamine levels and thus may contribute more significantly to bAR signaling in conditions of catecholamine excess such as HF and mitral regurgitation (MR) [17, 34] . In the healthy, non-failing heart, b 3 AR activation inhibits cardiac myocyte contraction and induces cardiac myocyte relaxation [15] . However, the effect of b 3 AR signaling on cardiac contractility remains incompletely understood, as both negative [40] and positive [7] inotropic effects have been demonstrated with b 3 AR stimulation in diseased, failing hearts. Importantly, transgenic mice with cardiac-specific overexpression of human b 3 AR show enhanced cardiac contractility [26] and attenuated neurohormone-induced hypertrophic remodeling [5] .
Gene expression analysis of left ventricular (LV) tissue recently revealed that cardiac bAR and NO signaling pathways are markedly altered in patients with isolated MR compared to control subjects [66] . Yet how the interaction between bAR and NO signaling differs in the stressed and pathologically remodeled heart is not fully understood. We previously demonstrated that NO-sGC-cGMP signaling is dysregulated in animal models of concentric and eccentric cardiac hypertrophy with respect to myocardial expression, subcellular localization, and oxidation of sGC heterodimer subunits [29, 57] .
In prior studies, chronic b 1 B therapy preserved normal cardiac myocyte contractility and enhanced bAR responsiveness in the experimental chronic MR canine model after four months of treatment [43] . In the present study, we used a 4-week chronic MR canine model to investigate the early effects of chronic b 1 B therapy on myocardial NOsGC-cGMP signaling as well as b 3 AR/NO-cGMP coupling. We hypothesized that chronic b 1 B therapy preserves normal NO-sGC-cGMP signaling and enhances myocardial b 3 AR/NO-cGMP coupling in a microdomain-specific fashion, thereby potentially mediating later cardiac myocyte functional benefits. We focused on signaling within and outside of myocardial caveolae-small, flask-shaped, lipid-and protein-rich invaginations of the plasma membrane (PM) that compartmentalize signal transduction. Importantly, all three bAR subtypes [2, 30, 45, 47, 49] , eNOS [23] , nNOS [9] , sGC [57] , and calcium channels [32, 33] , reside within caveolae; some, exclusively.
Methods

Animal experiments
Mitral regurgitation (MR) was induced in conditioned mongrel dogs (19-26 kg) by rupturing a papillary chord under fluoroscopy, as previously described [25, 29, 46] . Sixteen dogs underwent chordal rupture and ten unoperated dogs served as controls. At 24 h after MR induction, half of the MR dogs were started on metoprolol succinate 100 mg by mouth once daily (MR n = 8, MR?bB n = 8). Twodimensional and M-mode echocardiography (2.25-MHz transducer, ATL Ultramark VI) was performed at baseline and at the time of euthanasia (4 weeks after MR induction). Animals were maintained at a deep plane of general anesthesia using isoflurane and were mechanically ventilated. At the end of the in vivo experiments, the heart was arrested with intracardiac injection of KCl and quickly extirpated and placed in phosphate-buffered ice slush. The coronaries were flushed with oxygenated Krebs solution. A portion of the LV was cut and snap-frozen in liquid nitrogen for subsequent studies. We chose to study 4 Total RNA was extracted from flash-frozen LV myocardium using a spin column chromatography method (Animal Tissue RNA Purification Kit, Norgen Biotek, Ontario, Canada), according to the manufacturer's instructions. Reverse transcription (RT) was performed using the SuperScript III FirstStrand Synthesis System (Invitrogen, Life Technologies) and oligo-dt primers according to the manufacturer's instructions. Real-time PCR (qPCR) was performed using QuantiFast SYBR Ò Green PCR Kit (Qiagen). Data were normalized to large ribosomal protein P1 (RPLP1) RNA expression. The following primer sets were used (forward, reverse):
0 ); RPLP1 (proprietary primer sequences, Qiagen). Individual samples were run in triplicate.
Isolation of caveolin-3-enriched lipid raft fraction by isopycnic ultracentrifugation Caveolae-enriched lipid raft fractions (Cav3 ? LR) were prepared from snap-frozen LV tissue, using a discontinuous 35-5 % sucrose density gradient ultracentrifugation method as previously described [29, 57] . LV tissue homogenization was carried out on ice, in detergent-free buffer (50 mmol/L Tris-HCl, pH 7.6, 1 mmol/L EDTA, 1 mmol/L DTT, 2 mmol/L PMSF, 50 mmol/L NaF, 1 mmol/L Na Vanadate) with protease inhibitors (Mammalian Cocktail, Sigma-Aldrich). Following 1-h incubation on ice with intermittent vortex, 0.6 mL of tissue homogenate was mixed with 1.4 mL of 60 % (w/w) sucrose in 20 mmol/L KCl, 0.5 mmol/L MgCl 2 and placed at the bottom of an ultracentrifuge tube. A discontinuous 35-5 % sucrose gradient was formed by overlaying each sample with 1.3 mL of 35 % sucrose and then with 1.3 mL of 5 % sucrose. The sucrose density gradient was topped off with 0.5 mL of 200 mmol/L KCl. Each sample was then centrifuged at [180,000g for 16-18 h at 4°C in a swinging bucket rotor (Beckman Instruments, Palo Alto, CA) without any brake. The top KCl layer was discarded and fractions were collected every 400 ll from the top sucrose layer corresponding to F1 (top, most buoyant) to F11 (bottom, least buoyant/heaviest).
A light-scattering band confined to the 35-5 % sucrose interface, typically F3-F5, corresponds to Cav3
? LR fractions. Ponceau staining and protein concentrations determined by bicinchoninic acid (BCA) assay confirmed that total protein distribution was weighted toward heavier sucrose density gradient fractions (F7 through F11) lacking caveolin-3 (Cav3) in all hearts. Proteins were precipitated using 0.1 % w/v deoxycholic acid in 100 % w/v trichloroacetic acid. Protein concentrations were determined by BCA protein assay (Pierce). Non-lipid raft (NLR, F11) and Cav3
? LR fractions (F3-F5) without TCA precipitation were also collected for BCA and subsequent cGMP assays.
Cav3
? LR fractions were selected based upon greatest enrichment of Cav3 as detected by Western.
Cardiomyocyte caveolae-immunoaffinity isolation
Cardiomyocyte caveolae organelles were isolated using a immunoaffinity protocol [42] . In brief, sheep anti-mouse IgG-coated magnetic beads (Dynabeads, Life Technologies, Carlsbad, CA) were pre-incubated with a monoclonal antibody specific for caveolin-3 (BD transduction) for 2 h at room temperature. Control beads were pre-incubated in PBS only. Both anti-Cav3 Dynabeads and control IgG Dynabeads were subsequently washed with PBS for 1 h at 4°C on a rotator.
Plasmalemmal membrane rafts were fractionated from ventricular myocardial tissue as previously reported [44] . Canine LV (100 mg) was dounce homogenized in 1 mL ice cold, detergent-free Tricine buffer (20 mM Tricine, 1 mM EDTA, 250 mM sucrose, pH 7.4) and centrifuged at 1,000g for 10 min at 4°C. Cell pellets were resuspended in 1 mL Tricine buffer, dounce homogenized, and centrifuged again at 1,000g for 10 min at 4°C. An aliquot of pooled supernatant (30 ll) was set aside as the homogenate (H) sample. The pooled supernatant was then mixed with 30 % Percoll (Sigma) in Tricine buffer and subjected to ultracentrifugation at [116,000g for 30 min at 4°C (Beckman MLS50 rotor, 33,000 rpm, no break). The separated PM was collected, mixed with ice-cold MBS buffer (20 mM 2 N-morpholinoethane-sulfonic acid, 20 mM KCl, 135 mM NaCl), and microcentrifuged at approximately 21,000g for 30 min at 4°C to pellet the membrane. The supernatant was discarded. The membrane pellet was resuspended in ice cold 1 mL PBS and sonicated on ice (30 s bursts 9 3). An aliquot (30 ll) was set aside as the PM for subsequent Western blotting.
Remaining PM was incubated with the anti-Cav3-coated Dynabeads for 1 h at 4°C, using a rotator. Bound material (B), representative of cardiomyocyte caveolae vesicles, was separated magnetically from unbound (U), non-caveolae membranes. An aliquot (30 ll) of the unbound fraction (U) was set aside for subsequent Western blotting. Using the magnetic rack, beads were washed five times with PBS, resuspended in 29 loading buffer (100 mM Tris, pH 6.8, 2 % SDS, 0.02 % bromophenol blue, 20 % glycerol, 100 mM DTT), and boiled at 95°C for 5 min to dissociate the protein from the beads. Homogenate (H), PM, bound material representative of cardiomyocyte caveolae (B), and unbound material representative of noncaveolae plasmalemmal membrane (U) were subjected to SDS-PAGE and immunoblotted using the indicated antibodies.
Western analysis
Protein extracts were run on SDS-PAGE gels, transferred to nitrocellulose membranes, and immunoblotted using primary antibody probes as follows: b 3 AR (1:1,000, Abnova); sGCa 1 (1:1,000, Abcam); sGCb 1 (1:4,000, Cayman Chemicals); Cav3 (1:10,000, BD Transduction); total nNOS (1:1,000, BD Transduction); phospho-nNOS (Ser 1412 p-nNOS, 1:1,000, gifted by K.J. Hurt, University of Colorado) [20] ; GAPDH (1:10,000, cell signaling). Specificity of anti-sGCa 1 and -b 1 antibodies was confirmed using protein extracts from sGCa 1 -/-and sGCb 1 -/-mouse hearts as previously published [57] . Primary antibody binding was visualized by either horseradish peroxidaseconjugated secondary antibodies with enhanced chemiluminescence (GE Healthcare) or Alexa Fluor 680 or 800-conjugated secondary antibodies (molecular probes) with an Odyssey infrared imager (LI-COR). Densitometry analysis of immunoblots was performed using Image J Software (NIH) or Image Studio Software (Odyssey CLx v2.1, LI-COR).
sGC activity assay and redox state determination Baseline and agonist-stimulated cGMP levels of total LV, Cav3
? LR, and NLR from Control, MR, and MR?bB hearts were measured by direct cGMP ELISA kit (New East Biosciences, Malvern, PA), as previously described [29, 57] . LV homogenates, Cav3
? LR and NLR membrane fractions were pre-incubated at room temperature for 15 min in a solution for final concentrations of Tris 50 mM, pH 7.6, IBMX (3-isobutyl-1-methylxanthine) 0.75 mmol/L, creatine phosphate 3.5 mmol/L, creatinine phosphokinase 1 unit, GTP 1 mmol/L, and MgCl 2 3 mmol/L. Samples were then incubated with or without DEA/NO (1 lmol/L) or BAY 60-2770 (0.01 lmol/L) at 37°C for 10 min and subjected to diethyl ether extraction. cGMP levels of ether-extracted samples were measured by EIA according to kit manufacturer protocol. BAY60 compound was provided by J-P Stasch (Bayer AG, Wuppertal, Germany).
In vitro functional assays of b 3 AR/NO-cGMP coupling Selective b 3 AR agonist BRL 37344 (BRL, 0.1 and 1.0 lmol/L, Tocris Bioscience) was used to assess b 3 AR induction of NO-sGC-cGMP signaling. cGMP levels were measured as above.
Statistical analysis
All values are expressed as mean ± SEM. Statistical analyses were performed using: two-way ANOVA when determining interaction of conditions or the source of variance; one-way ANOVA followed by Tukey or HolmSidak's multiple comparison test as appropriate; BrownForsythe test of variance, if relevant; and two-tailed paired, ratio paired, or one-tailed unpaired Student's t test, as appropriate. Statistical significance was defined as P \ 0.05. GraphPad Prism 6.0 was used for statistical and graphical analysis.
Results
MR-induced early eccentric remodeling persists and normal LV function remains preserved following 4 weeks of metoprolol therapy
As expected, dogs developed increased LV chamber dilation and decreased LV wall thickness to end-diastolic dimension, by 4 weeks post-MR induction, irrespective of metoprolol therapy (Table 1) . LV fractional shortening remained normal in Control, MR, and MR?bB hearts at 4 weeks.
Chronic metoprolol therapy increases myocardial b 3 AR expression without altering membrane microdomain distribution Although expressed at low levels in the normal adult heart, b 3 AR is upregulated in the concentric hypertrophied and failing heart [8, 35, 60, 65] . We induced early stage eccentric hypertrophy via MR-mediated chronic volume overload in dogs, as previously described [29] , treated some MR dogs with b 1 B metoprolol succinate (MR?bB), and measured b 3 AR mRNA and protein expression as well as b 3 AR membrane microdomain distribution, comparing control, MR, and MR?bB animals. b 3 AR mRNA expression, normalized to housekeeping gene RPLP1, increased 4.4 9 10 3 -and 3.2 9 10 2 -fold in MR and MR?bB, respectively, relative to control (Fig. 1a) . We detected b 3 AR by Western immunoblot at its predicted molecular weight of 43 kDa in both isolated adult canine cardiac myocytes and canine LV myocardium (Fig. 1b) . Sensitivity and specificity of our b 3 AR antibody was demonstrated by immunoblotting various tissue and fractions known to have differential b 3 AR expression. As expected, b 3 AR expression was enriched in the PM fraction of murine LV relative to LV total protein. Our immunoblot likewise confirmed greater hepatic than myocardial b 3 AR expression [62] . b 3 AR expression was also greater in LV of human b 3 AR expressing transgenic mice than of wild type mice [5] . Chronic b 1 AR-blockade potentiated the increase in myocardial b 3 AR expression in MR, with 1.4 ± 0.1-fold and 1.9 ± 0.2-fold higher expression in MR and MR?bB, respectively, than in Control (Fig. 1c, d) . We also examined the distribution of b 3 AR in myocardial membrane microdomains as resolved by isopycnic ultracentrifugation. b 3 AR was detected within caveolae microdomains (Cav3 ? LR, F4-F5) and heavy density, non-lipid raft membrane fractions (NLR, F11) of all hearts (Fig. 1e) . While overall expression varied amongst the study groups, distribution of b 3 AR across myocardial membrane fractions was similar (Fig. 1f) . Caveolae localization of b 3 AR within cardiomyocytes was further verified by plasmalemmal caveolae-immunoaffinity isolation and immunoblot analysis (Fig. 1g) . Since only myocytes exclusively express Cav3, caveolae-immunoaffinity isolation using anti-Cav3-antibody-coated magnetic beads ensured selection of only myocyte caveolae, and not that of endothelial cells, fibrocytes, or adipocytes. (Fig. 2a) . b 3 AR stimulation at increasing concentrations of BRL did not induce cGMP production within Cav3 [1, 5, 41, 60] . While eNOS activation by b 3 AR is inconsistently reported amongst various animal and human models [1, 40, 41, 60] , recent in vitro studies of isolated neonatal rat ventricular cardiac myocytes and in vivo mouse studies demonstrated cardioprotective b 3 AR signaling mediated via nNOS activation, specifically through Ser 1412 phosphorylation of nNOS [5, 41, 60] . To corroborate the role of this mechanism in BRL-induced cGMP production within MR?bB NLR, we assessed Ser 1412 p-nNOS and total nNOS by Western blot in BRL-stimulated NLR of Control, MR, and MR?bB hearts (Fig. 3a) . Increased phosphorylation of nNOS upon BRL stimulation was detected in NLR of MR?bB but not MR or Control (Fig. 3b) . These results are consistent with b 3 AR/NO-cGMP coupling in the NLR domain in a b 1 B therapy-dependent manner.
Effect of b 1 AR-blockade on myocardial membrane microdomain distribution of sGC subunits As we have previously shown, a 1 and b 1 subunits of the sGC heterodimer localize to both Cav3
? LR and NLR but differentially relocalize in the hemodynamically stressed heart. Under pressure-and volume-overload cardiac stress, sGCb 1 relocalizes away from Cav3 ? LR [29, 57] . Here, the distribution of sGCa 1 was unperturbed by either volume overload or chronic b 1 AR-blockade at this 4 week time point (Fig. 4a) . Interestingly, chronic b 1 AR-blockade prevented the shift of sGCb 1 towards NLR that was otherwise observed in MR hearts. In MR?bB, Cav3
? LR localization of sGCb 1 was preserved and relocalization of sGCb 1 to heavy density, NLR was abated (Fig. 4b) .
Chronic b 1 AR-blockade is associated with less oxidized and more reduced sGC Given the observed membrane distribution of the sGC subunits and b 3 AR, physical colocalization of these proteins alone would not explain the functional coupling of b 3 AR and NO-sGC-cGMP signaling detected exclusively within NLR of MR?bB. We hypothesized that chronic b 1 AR-blockade may have impacted the redox state of sGC within the various membrane microdomains. Dependent upon its ferrous heme moiety, inducible cyclase activity of the sGC heterodimer varies with its redox state. Oxidized sGC does not respond normally to NO. Heme-free sGC is unresponsive to NO stimulation. sGC activators (e.g. BAY60) can stimulate sGC cyclase activity independent of NO or heme; oxidized sGC has a relatively potentiated response to sGC activators [24] . Thus, differential cyclase response of sGC to BAY60 versus NO-donor DEA/NO can reveal its redox state [48] . We previously showed that while NLR-localized sGC becomes oxidized in the volume-overloaded heart, caveolae-localized sGC does not g Cardiac myocyte plasmalemmal caveolae organelles were immunoaffinity-purified with anti-Cav3. b 3 AR was detected LV homogenate (H), LV plasmalemmal membrane fraction (PM), cardiomyocyte plasmalemmal caveolae (B bound fraction), and in LV plasmalemmal membrane depleted of caveolae (U unbound fraction) [29] . We measured cGMP levels of LV total protein extracts, Cav3
? LR, and NLR at baseline and following stimulation with DEA/NO and BAY60, all in the presence of IBMX (Fig. 5) . BAY60-induced cGMP production exceeded DEA/NO-induced cGMP production in MR and MR?bB, suggesting an overall predominance of oxidized sGC in the volume-overloaded heart. However, BAY60-induced cGMP production in MR?bB was similar to that in Control, both lower than in MR, suggesting that chronic b 1 AR-blockade blunts oxidation of sGC in the volumeoverloaded heart (Fig. 5a) . Alternatively, differential cyclase activity could reflect differential expression of sGC. Immunoblots of sGC subunits confirmed that sGCb 1 expression did not vary amongst Control, MR, and MR?bB (Fig. 6) . While sGCa 1 levels fell slightly in MR?bB compared to either Control or MR, there was no impact on either basal or NO-inducible sGC activity.
Baseline and DEA/NO-stimulated cGMP levels were similar for total protein extracts of all hearts.
We again found that caveolae localization protected sGC from oxidation in all hearts. In Cav3
? LR, inducible sGC cyclase activity was similar for all study groups (Fig. 5b) . Notably, the response to BAY60 was not potentiated within Cav3
? LR, relative to control or DEA/ NO. In fact, DEA/NO-induced cGMP production exceeded that of BAY60 within Cav3
? LR, most significantly for MR and MR?bB, suggesting a predominance of reduced sGC within caveolae. As we previously reported oxidation of sGC within MR NLR, we hypothesized that chronic b 1-blockade might prevent this stress-induced change in NLRlocalized sGC. Indeed, we found that NLR-localized sGC was not oxidized in MR?bB (Fig. 5c) . The BAY60 response of MR?bB NLR was markedly blunted compared to that of MR NLR and similar to that of Control NLR.
Discussion
We demonstrated that chronic b 1 B in MR is associated with enhanced myocardial NO-sGC-cGMP signaling and b 3 AR/ NO-cGMP coupling in specific membrane microdomains. Although myocardial b 3 AR expression was slightly increased, b 3 AR/NO-cGMP coupling could not be detected in untreated MR hearts. Increased oxidation of sGC in MR may have accounted for the lack of b 3 AR/NO-cGMP coupling. In contrast, MR?bB hearts had greater upregulation of myocardial b 3 AR expression, improved sGC redox state, and detectable b 3 AR/NO-cGMP coupling, specifically in heavy-density membrane microdomains. These early changes in myocardial b 3 AR signaling at 4 weeks of metoprolol therapy in MR may contribute to the subsequent potentiated bAR responsiveness and improved cardiac myocyte and LV function seen after more prolonged 4-month metoprolol therapy [43] .
Although the functional role of b 3 AR upregulation in HF had been widely debated, several recent studies have clearly shown a cardioprotective role for cardiac b 3 AR signaling. Chronic BRL treatment blunted pathologic cardiac remodeling and improved cardiac function, via a proposed restoration of the nitroso-redox balance, in mice subjected to pressure-overload cardiac stress. [41] . Similarly, transgenic LR in any study group (not shown). All measurements were in the presence of IBMX. Averaged baseline cGMP levels included 10-12 measurements, including replicates, per study group. For summary analysis of BRL stimulated cGMP production, only paired baseline and BRL-induced cGMP levels were included, n = 4-6 per study group. For each BRL dose, one-way ANOVA P B 0.1, *P \ 0.05, and P B 0.1 on unpaired student t test. For BRL 0.1 lM dose, Brown-Forsythe P \ 0.05 Table 2 b Summary densitometry analysis of all hearts analyzed (n = 4-7 per study group). One-way ANOVA for sGCb 1 P = 0.012 for F4, P = 0.007 for F9, P = 0.031 for F11. Unpaired student t test *P \ 0.05 for MR vs. control, P \ 0.05 for MR?bB vs. MR, à P \ 0.10 for MR?bB vs. MR mice with cardiac myocyte-specific expression of human b 3 AR had attenuated hypertrophic response to chronic isoproterenol and angiotensin II stimulation [5] . Cardiac-specific b 3 AR transgenic mice have also been shown to have enhanced cardiac contractility [26] . Furthermore, improved cardiac function and metabolism in a diabetic rat model was associated with metoprolol-induced upregulation of b 3 AR signaling [50, 51] .
In the studies reported here, we interrogated a presumed myocardial b 3 AR/NO-cGMP signaling pathway to investigate this as a potential mechanism of cardiac benefit for metoprolol. We previously demonstrated that volumeoverload cardiac stress disturbs the nitroso-redox balance as reflected by increased oxidation of sGC in the myocardium [29] . Chronic b 1 AR-blockade not only prevented the nitroso-redox imbalance in volume-overloaded hearts, as reflected by decreased oxidation of sGC in MR?bB hearts, but also induced coupling of b 3 AR and NO-sGC-cGMP signaling in a membrane microdomain specific fashion.
Using the selective b 3 AR agonist BRL, we tested the capacity for b 3 AR triggered cGMP production within LV myocardium, caveolae, and heavy-density, NLR. We compared the BRL response to the DEA/NO response to assess the relative coupling between b 3 AR and NO-sGC-cGMP normalized to Control. Mean of replicate measures was used for each heart sample. Bar graph represents group mean ± SEM. Total dogs analyzed: Control n = 6, MR n = 5, and MR?bB n = 4. One-way ANOVA P = 0.007 for sGCa 1 ; P = 0.095 for sGCb 1 signaling. Given reports of caveolae localization of a b 3 AR isoform in mice and of human b 3 AR in a cardiacspecific transgenic mouse [5, 47] , along with overall upregulation of b 3 AR in metoprolol-treated diseased hearts [50] [51] [52] , we expected to find enhanced b 3 AR/NOcGMP coupling specifically within caveolae of MR?bB hearts. Strikingly, chronic metoprolol therapy enhanced b 3 AR/NO-cGMP coupling within NLR, not Cav3
? LR, of the eccentric hypertrophied heart. In MR hearts, b 3 AR did not increase cGMP production in any myocardial microdomain despite upregulation of b 3 AR. This discrepancy between b 3 AR upregulation and coupling with NO-sGCcGMP may be explained by the relocalization of sGCb 1 away from caveolae and the oxidation of sGC within NLR of MR hearts. While the potential signaling partners may be within a shared membrane microdomain, it appears that inducible sGC cyclase activity was compromised by oxidation.
Alternatively, coupling of b 3 AR and NO-sGC-cGMP within MR?bB NLR might reflect local coupling of b 3 AR and nNOS. Recent studies in rodents demonstrated that b 3 AR signaling activates nNOS, as the effects of b 3 ARmediated cardioprotection, NO production, and NOS signaling were blunted in mice with genetically deleted nNOS [41] . Moreover, b 3 AR activation of nNOS was found to occur via phosphorylation of the nNOS positive regulatory site, Ser 1412 [5, 41, 60] . While levels of Ser 1412 -phosphorylated nNOS (p-nNOS) are low under physiological conditions, nNOS activation, as reflected by elevated Ser 1412 p-nNOS, may play a critical counter-regulatory role in stress induced, pathophysiological conditions. In our canine model, selective b 3 AR agonist BRL induced an increase in Ser 1412 p-nNOS within NLR of MR?bB but not in MR or Control, which is consistent with our findings of BRL-induced cGMP production within NLR of MR?bB alone. These findings as a whole suggest that b 1 ARblockade within the volume-overloaded heart induces b 3 AR/NO-cGMP coupling via enhanced b 3 AR activation of nNOS.
Our findings regarding b 3 AR and NO-sGC-cGMP signaling are novel and significant on several fronts. We are the first to demonstrate active and inducible coupling of b 3 AR and NO-sGC-cGMP signaling within the heart, notably in the b 1 B-treated, volume-overloaded heart and in a microdomain specific fashion. Recent studies of a double transgenic mouse with cardiac myocyte-specific expression of both the human b 3 AR and a cGMP-specific FRET sensor revealed increased basal sGC activity [5] . However, inducible or active coupling between b 3 AR and NO-sGCcGMP was not interrogated. Our findings suggest that chronic b 1 B therapy is associated with a beneficial inducible and active b 3 AR/NO-cGMP coupling outside of myocardial caveolae. This is consistent with reports of (a) differential subcellular localization and G protein coupling of murine b 3 AR isoforms [47] ; and (b) G i mediation of GPCR activation of NOS [3, 10] . Moreover, previously reported nuclear b 3 AR regulation of gene transcription depends upon local downstream NO-sGC-cGMP activation [58] . While more studies are warranted to elucidate the mechanistic details, such reports of nuclear b 3 AR activation of NO-sGC-cGMP signaling raise the possibility that the NLR microdomain may encompass nuclear envelope.
Interestingly, chronic metoprolol treatment was associated with the retention of sGCb 1 within caveolae. As the exact mechanism of caveolae localization of sGCb 1 remains to be determined, we can only hypothesize at this time that chronic b 1 AR-blockade either directly or indirectly impacts upon protein-protein interactions or reversible post-translational modifications (e.g. S-palmitoylation) that are generally believed to mediate caveolae localization [11, 22, 63] . Such studies are beyond the scope of this manuscript.
Myocardial b 3 AR expression is challenging to assess given the low expression of b 3 AR relative to b 1 AR and b 2 AR in the heart [36] . While radioligand binding assays are commonly used to determine receptor expression, highaffinity and high-specificity radiolabeled bAR subtype antagonists are necessary to differentiate the relative expression of the three bAR subtypes. In adipose tissue, which predominantly expresses b 3 AR over either b 1 AR or b 2 AR, radioligand binding assays are feasible for determining b 3 AR expression. However, the lack of highaffinity, selective b 3 AR antagonists precludes the use of radioligand binding assays for determining b 3 AR expression and distribution in the heart [12, 37, 39] . The exceedingly high concentration of radioligand b 3 AR antagonist needed would lead to high non-specific binding and inaccurate characterization of b 3 AR expression. Hence, in lieu of radioligand binding assay, we selected a highly sensitive and specific b 3 AR antibody that recognizes an epitope conserved within both canine and human b 3 AR amino acid sequences and has only 60-80 % identity, at high E values, with b 1 AR or b 2 AR amino acid sequences. We confirmed our Western analysis with qRT-PCR. Most importantly, we successfully demonstrated functional coupling of b 3 AR/NO-cGMP signaling with our in vitro BRL stimulation studies.
Our assessment of myocardial microdomain signaling is, by necessity, synthetic in nature, in that cyclase activity assays are performed on myocardial membrane fractions, as opposed to live, intact cardiac myocytes. Ideally, subcellular cGMP signaling within caveolae-and heavy-density NLR microdomains could be visualized in live cells with a FRET-based cGMP sensor. While transgenic mice with cardiac myocyte-specific expression of FRET-based cGMP sensors have recently been reported [5, 56] , none are microdomain-targeted cGMP sensors. Thus, our combinatorial approach of cGMP enzyme immunoassays and Western analyses effectively allow us to interrogate microdomain signaling.
This study shows for the first time that chronic b 1 B with metoprolol therapy preserves and even enhances NOcGMP signaling within specific myocardial microdomains in the volume-overloaded heart, in particular inducing coupling of b 3 AR/NO-cGMP signaling in the heavy-density non-lipid raft fraction. The present analysis raises the possibility that the antioxidant action shared by bBs may be an indirect restoration of nitroso-redox balance in myocardial NLR membrane microdomain, mediated by enhanced b 3 AR signaling coupled with nNOS activation and sGC stimulation (Fig. 7) . This indirect antioxidant mechanism may be particular to selective b 1 -blockers, or even metoprolol succinate for that matter. Whereas metoprolol upregulates myocardial b 3 AR expression, the nonselective b-blocker carvedilol does not [64] . Whereas carvedilol can directly scavenge free radicals, selective b 1 -blockers do not [54] . In fact, carvedilol has been shown to block oxidative stress-mediated signaling via various mechanisms [27] . Thus, the comparative cardioprotection and cardioprotective mechanism of b 1 B metoprolol versus non-selective bBs may depend upon the etiology of HF and thereby the effect of the specific cardiac injury upon myocardial NO and/or b 3 AR signaling [28] . Regardless, the enhancement of myocardial b 3 AR/NO-cGMP coupling with chronic b 1 AR-blockade in the volume-overloaded heart suggests new approaches to bAR modulation to optimize cardiac function. bAR modulation, with initial chronic b 1 AR antagonism followed by additional b 3 AR agonism, may offer further functional and clinical benefit to HF and MR patients. Moreover, direct stimulation of myocardial sGC on a background of neurohormonal blockade may similarly confer additional clinical benefit [13] . Such potential therapeutic implications warrant further mechanistic and eventual clinical studies. 
